HC Wainwright Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $27.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 37.76% from the stock’s current price. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.20 EPS, Q4 2025 earnings at $0.24 EPS and FY2029 earnings at $2.32 EPS.

A number of other equities analysts have also commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target on the stock. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Finally, StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Stock Up 1.3 %

NASDAQ:ACAD opened at $19.60 on Thursday. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $24.53. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of 25.13 and a beta of 0.37. The company’s 50 day moving average is $18.37 and its 200-day moving average is $16.81.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth $2,106,000. Mackenzie Financial Corp boosted its stake in ACADIA Pharmaceuticals by 180.1% during the fourth quarter. Mackenzie Financial Corp now owns 51,065 shares of the biopharmaceutical company’s stock worth $937,000 after buying an additional 32,833 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth $64,000. CTC Alternative Strategies Ltd. acquired a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $1,012,000. Finally, Neo Ivy Capital Management boosted its stake in shares of ACADIA Pharmaceuticals by 1,551.5% in the 4th quarter. Neo Ivy Capital Management now owns 57,504 shares of the biopharmaceutical company’s stock valued at $1,055,000 after purchasing an additional 54,022 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.